| 摘要 |
Provided is the use of a specified CTLA4 mutant molecule comprising an extracellular domain beginning with alanine at position 26 or methionine at position 27 and ending with aspartic acid at 5 position 150, or a functional portion thereof, wherein in the extracellular domain or functional portion thereof an alanine at position 55 is substituted with a tyrosine, and a leucine at position 130 is substituted with a glutamic acid, in the manufacture of a medicament for treating an immune disorder associated with graft transplantation, wherein the subject has received an alternate immunosuppressive therapy post transplantation, wherein the administration regimen comprises a conversion from the alternate immunosuppressive therapy to the CTLA4 mutant molecule, and wherein the alternate immunosuppressive therapy is decreased over an appropriate period of time and the CTLA4 mutant molecule is administered more frequently than monthly. (62) Divided Out of 561655 |
